Ecs Botanics Holdings Ltd · ASX:ECS

Ecs Botanics — Shareholder Meeting (November 2026)

12 slides from Ecs Botanics's shareholder meeting presentation, Nov 18, 2026

  1. Slide 1: 2026 Annual General Meeting

    rsonal use only ECS Botanics Holdings Ltd 2026 Annual General Meeting Jeremy King Chairman ASX : ECS Nan-Maree Schoerie 18 NOVEMBER 2026 CEO and Managing Director

  2. Slide 2: Disclaimer

    Disclaimer rsonal use only This presentation has been prepared by ECS Botanics recommendation in relation to the purchase or sales of contractors or agents about the accuracy, completeness Holdings Limited (“Company”). shares or other securities in any jurisdiction. or fairness of any information or

  3. Slide 3: FY26 marked a material improvement in financial and operating performance

    FY26 marked a material improvement in ECS’s financial and operating performance rsonal use only Revenue Branded B2C $21.4m $3.45m ▲ 10% YoY Q4 sales, ▲ 31% YoY; ~71% of Q4 revenue EBITDA Production +$0.6m 5.3 tonnes PCE production ▲ 43% YoY Improved by $5.8m YoY Outdoor trimmed flower ▲ 12% Operatin

  4. Slide 4: From cash burn to sustained positive operating cash flow

    From cash burn to sustained positive operating cash flow rsonal use only FY25 Operating Cash Flow Receipts and Net Operating Cashflow ($'000s) -$5.1m $6,000 $500 $5,000 $0 FY26 Operating Cash Flow $4,000 +$0.5m ($500) $3,000 $5.6m YoY improvement ($1,000) $2,000 Q1 FY27 Operating Cash Flow $1,000 ($

  5. Slide 5: FY27 has started with continued commercial momentum

    FY27 has started with continued commercial momentum rsonal use only Quarterly Sales OzSun Flower $5.49m $1.33m ▲ 13.1% QoQ ▲ 44.5% YoY Branded B2C Sales Market Momentum $3.91m ▲ 11.9% QoQ ▲ 23.9% YoY, ~71% of sales vs broader tracked panel ▼ 1.9%1 1: Nostradata pharmacy panel subset; indicative only

  6. Slide 6: The next proof points are commercial

    The next proof points are commercial  Continue taking market share with Australian-grown products Grow Australian brands  Expand selected branded formats rsonal use only  Build adoption across OzSun, AVANI & differentiated finished-dose products I N V E S T O R  Build recurring revenue across Ge

  7. Slide 7: Existing infrastructure provides capacity for further growth

    Existing infrastructure provides capacity for further growth rsonal use only Operational FY26 outdoor FY26 PCE Production cost per cultivation trimmed flower production gram infrastructure 3.1 tonnes 5.3 tonnes Reduced 26 PCEs ▼ 33% PCE Protective cropping ▲ 12% YoY ▲ 43% YoY ▼ 44% Outdoor enclosure

  8. Slide 8: Branded B2C sales up 23.9% YoY as the portfolio broadens

    Branded B2C sales up 23.9% YoY as the portfolio broadens rsonal use only I N V E S T O R P R E S E N T A T I O N OzSun AVANI Portfolio expansion Value-led Australian-grown portfolio Differentiated finished-dose products Premium brands and differentiated formats $1.33m +35.7% Q1 flower sales YoY caps

  9. Slide 9: Brands continue to scale as OzSun expands internationally

    Expanding Brands continue to scale as OzSun expands internationally Monthly Branded Product Australia Sales (AUD)) rsonal use only $1.6M $1.4M I N V E S T O R $1.2M $1.0M $0.8M $0.6M FY27 JUL-OCT $5.42m P R E S E N T A T I O N $0.4M $0.2M ▲ 21.7% YoY $0.0M June 2024 Oct 2024 Feb 2025 June 2025 Oct 2

  10. Slide 10: International pathways provide the next leg of commercial growth

    International pathways provide the next leg of commercial growth rsonal use only I N V E S T O R UK – Curaleaf Germany – established Poland - Koyi New Zealand – market entry finished-dose exports  Six ECS-branded P R E S E N T A T I O N Australian-grown flower  OzSun launched June  First flower r

  11. Slide 11: Differentiated IP and exclusive licences broaden the value proposition

    Differentiated IP and exclusive licences broaden the value proposition AVANI Advanced | VESIsorb® Terphogz® rsonal use only  Patented delivery technology designed to improve absorption  Award-winning Californian genetics brand I N V E S T O R and bioavailability of poorly water-soluble compounds 

  12. Slide 12: Thank You

    E C S B O T A N I C S H O L D I N G S L T D Thank You rsonal use only 2026 Annual General Meeting Call us today at 1300 833 988 Email us at info@ecs-botanics.com For investor and media enquiries: FY27 focus: Tim Dohrmann Branded growth | International execution | Operating leverage | Disciplined cas

ECS Botanics Holdings — Shareholder Meeting (November 2026) on 6ix